204 related articles for article (PubMed ID: 11497474)
1. Neck and whole-body scanning with 5-mCi dose of (123)I as diagnostic tracer in patients with well-differentiated thyroid cancer.
Gulzar Z; Jana S; Young I; Bukberg P; Yen V; Naddaf S; Abdel-Dayem HM
Endocr Pract; 2001; 7(4):244-9. PubMed ID: 11497474
[TBL] [Abstract][Full Text] [Related]
2. Comparison of 123I scintigraphy at 5 and 24 hours in patients with differentiated thyroid cancer.
Shankar LK; Yamamoto AJ; Alavi A; Mandel SJ
J Nucl Med; 2002 Jan; 43(1):72-6. PubMed ID: 11801706
[TBL] [Abstract][Full Text] [Related]
3. 123I isotope as a diagnostic agent in the follow-up of patients with differentiated thyroid cancer: comparison with post 131I therapy whole body scanning.
Alzahrani AS; Bakheet S; Al Mandil M; Al-Hajjaj A; Almahfouz A; Al Haj A
J Clin Endocrinol Metab; 2001 Nov; 86(11):5294-300. PubMed ID: 11701695
[TBL] [Abstract][Full Text] [Related]
4. The role of 123I-diagnostic imaging in the follow-up of patients with differentiated thyroid carcinoma as compared to 131I-scanning: avoidance of negative therapeutic uptake due to stunning.
Siddiqi A; Foley RR; Britton KE; Sibtain A; Plowman PN; Grossman AB; Monson JP; Besser GM
Clin Endocrinol (Oxf); 2001 Oct; 55(4):515-21. PubMed ID: 11678835
[TBL] [Abstract][Full Text] [Related]
5. The effect of posttherapy 131I SPECT/CT on risk classification and management of patients with differentiated thyroid cancer.
Grewal RK; Tuttle RM; Fox J; Borkar S; Chou JF; Gonen M; Strauss HW; Larson SM; Schöder H
J Nucl Med; 2010 Sep; 51(9):1361-7. PubMed ID: 20720058
[TBL] [Abstract][Full Text] [Related]
6. Sensitivity of 123I whole-body scan and thyroglobulin in the detection of metastases or recurrent differentiated thyroid cancer.
de Geus-Oei LF; Oei HY; Hennemann G; Krenning EP
Eur J Nucl Med Mol Imaging; 2002 Jun; 29(6):768-74. PubMed ID: 12029550
[TBL] [Abstract][Full Text] [Related]
7. Superiority of iodine-123 compared with iodine-131 scanning for thyroid remnants in patients with differentiated thyroid cancer.
Mandel SJ; Shankar LK; Benard F; Yamamoto A; Alavi A
Clin Nucl Med; 2001 Jan; 26(1):6-9. PubMed ID: 11139058
[TBL] [Abstract][Full Text] [Related]
8. Are posttherapy radioiodine scans informative and do they influence subsequent therapy of patients with differentiated thyroid cancer?
Fatourechi V; Hay ID; Mullan BP; Wiseman GA; Eghbali-Fatourechi GZ; Thorson LM; Gorman CA
Thyroid; 2000 Jul; 10(7):573-7. PubMed ID: 10958309
[TBL] [Abstract][Full Text] [Related]
9. Use of iodine-123 as a diagnostic tracer for neck and whole-body scanning in patients with well-differentiated thyroid cancer.
Berbano R; Naddaf S; Echemendia E; Barsa J; Turoglu H; Akisik M; Abdel-Dayem HM; Young I
Endocr Pract; 1998; 4(1):11-6. PubMed ID: 15251758
[TBL] [Abstract][Full Text] [Related]
10. Initial staging of differentiated thyroid carcinoma: continued utility of posttherapy 131I whole-body scintigraphy.
Donahue KP; Shah NP; Lee SL; Oates ME
Radiology; 2008 Mar; 246(3):887-94. PubMed ID: 18309016
[TBL] [Abstract][Full Text] [Related]
11. Absence of thyroid stunning after diagnostic whole-body scanning with 185 MBq 131I.
Cholewinski SP; Yoo KS; Klieger PS; O'Mara RE
J Nucl Med; 2000 Jul; 41(7):1198-202. PubMed ID: 10914909
[TBL] [Abstract][Full Text] [Related]
12. Detection of thyroid remnant/metastasis without stunning: an ongoing dilemma.
Park HM; Park YH; Zhou XH
Thyroid; 1997 Apr; 7(2):277-80. PubMed ID: 9133700
[TBL] [Abstract][Full Text] [Related]
13. The utility of I-123 pretherapy scan in I-131 radioiodine therapy for thyroid cancer.
Chen MK; Yasrebi M; Samii J; Staib LH; Doddamane I; Cheng DW
Thyroid; 2012 Mar; 22(3):304-9. PubMed ID: 22300251
[TBL] [Abstract][Full Text] [Related]
14. [The early detection of metastatic differentiated thyroid cancer using 131I total body scan and treatment with 131I].
Ikekubo K; Hino M; Ito H; Yamaguchi H; Saiki Y; Ui K; Tominaga E; Nakanishi M; Kawai J; Koh T
Kaku Igaku; 1991 Mar; 28(3):247-59. PubMed ID: 1904509
[TBL] [Abstract][Full Text] [Related]
15. A comparison between diagnostic I-123 and posttherapy I-131 scans in the detection of remnant and locoregional thyroid disease.
Thomas DL; Menda Y; Bushnell D
Clin Nucl Med; 2009 Nov; 34(11):745-8. PubMed ID: 19851166
[TBL] [Abstract][Full Text] [Related]
16. The usefulness of iodine-123 whole-body scans in evaluating thyroid carcinoma and metastases.
Yaakob W; Gordon L; Spicer KM; Nitke SJ
J Nucl Med Technol; 1999 Dec; 27(4):279-81. PubMed ID: 10646545
[TBL] [Abstract][Full Text] [Related]
17. Iodine-123 as a diagnostic imaging agent in differentiated thyroid carcinoma: a comparison with iodine-131 post-treatment scanning and serum thyroglobulin measurement.
Urhan M; Dadparvar S; Mavi A; Houseni M; Chamroonrat W; Alavi A; Mandel SJ
Eur J Nucl Med Mol Imaging; 2007 Jul; 34(7):1012-7. PubMed ID: 17256140
[TBL] [Abstract][Full Text] [Related]
18. The management of differentiated thyroid cancer using 123I for imaging to assess the need for 131I therapy.
Ali N; Sebastian C; Foley RR; Murray I; Canizales AL; Jenkins PJ; Drake WM; Plowman PN; Besser GM; Chew SL; Grossman AB; Monson JP; Britton KE
Nucl Med Commun; 2006 Feb; 27(2):165-9. PubMed ID: 16404230
[TBL] [Abstract][Full Text] [Related]
19. Association between residual thyroid carcinoma and diffuse hepatic uptake of 131I following radioiodine ablation in postoperative total thyroidectomy patients.
Tatar FA; Morita E; Ituarte PH; Cavalieri RR; Duh QY; Price DC; Siperstein AE; Clark OH
World J Surg; 2001 Jun; 25(6):718-22. PubMed ID: 11376405
[TBL] [Abstract][Full Text] [Related]
20. Effect of a diagnostic dose of 185 MBq 131I on postsurgical thyroid remnants.
Bajén MT; Mañé S; Muñoz A; García JR
J Nucl Med; 2000 Dec; 41(12):2038-42. PubMed ID: 11138690
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
